Quantcast
Last updated on April 16, 2014 at 11:32 EDT

Latest Macular edema Stories

2013-11-12 16:26:04

Detailed results from the Phase 3 VIBRANT trial of EYLEA in Macular Edema following Branch Retinal Vein Occlusion (BRVO) to be presented TARRYTOWN, N.Y., Nov. 12, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from several studies of EYLEA(®) (aflibercept) Injection will be presented during the annual meeting of the American Academy of Ophthalmology (AAO) to be held November 16-19 in New Orleans. EYLEA presentations will be featured during the...

2013-11-07 08:30:54

TARRYTOWN, N.Y., Nov. 7, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in the European Union (EU) for EYLEA(®) (aflibercept) Injection for the treatment of patients with Diabetic Macular Edema (DME). Regeneron has submitted a supplemental BLA for EYLEA in this indication to the U.S. Food and Drug Administration (FDA). "Diabetes is a growing,...

2013-10-21 08:28:31

TARRYTOWN, N.Y., Oct. 21, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results for EYLEA(®) (aflibercept) Injection from the Phase 3 VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO). In this trial, 53% of patients who received EYLEA 2 milligram (mg) every four weeks gained at least 15 letters in vision from baseline at week 24, the primary endpoint of the study, compared to 27% of...

2013-09-26 08:26:57

Exhibiting at the 13th Euretina Congress, the Angiogenesis Foundation invites visitors to explore its new multimedia resources on diabetic macular edema and central retinal vein occlusion. HAMBURG, Germany, Sept. 26, 2013 /PRNewswire/ -- The nonprofit Angiogenesis Foundation today launched two novel multimedia campaigns--the Science of DME and the Science of CRVO-- at the 13(th) Euretina Congress in Hamburg, Germany. These campaigns address the knowledge gap for two of the world's common...

2013-09-17 16:23:57

TARRYTOWN, N.Y., Sept. 17, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed results from the Phase 3 VIVID and VISTA trials of EYLEA(®) (aflibercept) Injection in Diabetic Macular Edema (DME) will be presented at an oral session during the upcoming annual meeting of the Retina Society to be held September 26-29 in Los Angeles, United States. These data will be presented on Friday, September 27, at 4:51 PM PDT. Separately, these data...

2013-08-29 04:21:08

TARRYTOWN, N.Y., Aug. 29, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO). "We are pleased with the approval of EYLEA in the E.U. in a second indication," said George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President of...

2013-08-06 04:21:15

U.S. and ex-U.S. regulatory submissions in diabetic macular edema expected in 2013; U.S. regulatory submission approximately one year earlier than previously planned TARRYTOWN, N.Y., Aug. 6, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA(®) (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg...

2013-07-26 08:25:53

TARRYTOWN, N.Y., July 26, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (CRVO). The decision of the European Commission is expected in the second half of 2013. "We are pleased with the positive...

2013-06-18 08:30:37

VANCOUVER, June 18, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME).  The study has shown a good safety profile with no drug-related serious adverse events to date. "The last patient was enrolled and treated on June 17," said Andrew Rae, President &...

2013-06-06 04:20:54

TARRYTOWN, N.Y., June 06, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced positive top-line results for EYLEA(®) (aflibercept) Injection from the Phase 3 MYRROR study in myopic choroidal neovascularization (mCNV). In this trial, patients receiving EYLEA at an initial dose of 2 milligrams (mg), followed by treatment on an as-needed (PRN) basis, had a mean improvement in best-corrected visual acuity (BCVA) from baseline at week 24 of...